The accelerating Emrosi prescription trajectory (36K TRx in Q2 vs 30K in Q1) and second consecutive quarter of positive Adjusted EBITDA signal a path to sustained profitability. Monitor the Q3 2026 earnings for continued Emrosi growth and operating leverage, as well as any updates on the term loan maturity schedule.
Price Chart
Executive Summary
Journey Medical reported Q2 2026 revenue of $18.5M (+23% YoY), beating the $18.4M consensus, and a narrower GAAP net loss of $0.3M (-$0.01 EPS vs -$0.02 consensus). Emrosi prescriptions grew to ~36,000 (up 20% QoQ), driving continued commercial momentum and positive Adjusted EBITDA of $2.9M, marking a second consecutive quarter of positive non-GAAP profitability.
Key Financial Metrics
Key Facts
- Total revenue of $18.5M for Q2 2026, up 23% YoY from $15.0M
- Emrosi revenue of $8.1M, driving growth; total Emrosi prescriptions ~36,000 vs ~30,000 in Q1 2026
- GAAP net loss narrowed to $0.3M ($0.01 loss per share) from $3.8M loss ($0.16 loss per share) in Q2 2025
- Positive Adjusted EBITDA of $2.9M for Q2 2026 vs negative $0.5M in Q2 2025
- Cash and cash equivalents of $25.6M at June 30, 2026, up from $24.1M at Dec 31, 2025
Financial Impact
Q2 2026 revenue of $18.5M (+23% YoY); GAAP net loss narrowed to $0.3M; positive Adjusted EBITDA of $2.9M
Risk Factors
- Generic competition risk for Emrosi or other products could erode market share
- Substantial doubt about going concern noted in forward-looking statements; company may need to raise additional capital
- Fortress Biotech controls a voting majority, limiting minority shareholder influence
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-094862 |
| Document: tm2622742d1_8k.htm | 0001104659-26-094862 |
| Document: 0001104659-26-094862-index-headers.html | 0001104659-26-094862 |
| Document: 0001104659-26-094862-index.html | 0001104659-26-094862 |
| Document: 0001104659-26-094862.txt | 0001104659-26-094862 |
| 8-K Data (Synthetic) | 0001104659-26-094862 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 16d ago | SC 13G/A | $6.31 | awaiting T+20 | — | $4.97 (−21.24%) |
Aug 15, 2026 10w ago | Institutional Cluster | $6.46 $7.36 | ▲ +13.93% | ▲ +15.91% | $4.97 (−23.07%) |
Aug 12, 2026 10w ago | 8-K | $6.65 $7.23 | ▲ +8.72% | ▲ +10.47% | $4.97 (−25.26%) |
Aug 12, 2026 10w ago | Press Release | $6.65 $7.23 | ▼ −8.72% | ▼ −10.47% | $4.97 (+25.26%) |
May 13, 2026 23w ago | 8-K | $6.35 $6.34 | ▼ −0.16% | ▲ +0.70% | $4.97 (−21.73%) |
May 6, 2026 24w ago | Press Release | $5.00 $6.06 | ▲ +21.20% | ▲ +18.06% | $4.97 (−0.60%) |
Apr 21, 2026 26w ago | Press Release | $4.92 $6.25 | ▲ +27.03% | ▲ +22.12% | $4.97 (+1.02%) |
Mar 25, 2026 30w ago | Press Release | $4.78 $5.15 | ▲ +7.74% | ▼ −2.92% | $4.97 (+3.97%) |
Mar 18, 2026 31w ago | Press Release | $7.12 $5.17 | ▼ −27.39% | ▼ −33.43% | $4.97 (−30.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers